Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (231-240 of 317) with videos related to

Pageof 32
Sort By:
Cancer Cell|February 7, 2025
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceFelicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
JCO Oncology Practice|August 9, 2022
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort StudyJesper van Breeschoten, Rawa K Ismail, Michel W J M Wouters, et al.
American Journal of Clinical Oncology|December 17, 2020
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 StatusJesper van Breeschoten, Michel W J M Wouters, Liesbeth C de Wreede, et al.
British Journal of Cancer|January 26, 2021
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
JCO Precision Oncology|September 21, 2022
<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced MelanomaOlivier J van Not, Willeke A M Blokx, Alfons J M van den Eertwegh, et al.
The Journal of Experimental Medicine|March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanomaIrene L M Reijers, Disha Rao, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2025
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanomaM Bloem, A J M van den Eertwegh, J B A G Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
The Lancet. Oncology|November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialSjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
Pageof 32

Showing results (231-240 of 317) with videos related to

Sort By:
Pageof 32
Cancer Cell|February 7, 2025
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordanceFelicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
JCO Oncology Practice|August 9, 2022
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort StudyJesper van Breeschoten, Rawa K Ismail, Michel W J M Wouters, et al.
American Journal of Clinical Oncology|December 17, 2020
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 StatusJesper van Breeschoten, Michel W J M Wouters, Liesbeth C de Wreede, et al.
British Journal of Cancer|January 26, 2021
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
JCO Precision Oncology|September 21, 2022
<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced MelanomaOlivier J van Not, Willeke A M Blokx, Alfons J M van den Eertwegh, et al.
The Journal of Experimental Medicine|March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanomaIrene L M Reijers, Disha Rao, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2025
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanomaM Bloem, A J M van den Eertwegh, J B A G Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
The Lancet. Oncology|November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialSjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
Pageof 32